The
A.S.H. sent their update today. Amazingly (for
them) for once their articles weren’t about money:
Early-Phase Trial Suggests CC-93269 Has Activity in Relapsed/Refractory Multiple Myeloma
In this small, first-in-human study, 43% of patients responded to treatment with the bispecific antibody, though a large portion of patients experienced a grade 3/4 adverse event.
In this small, first-in-human study, 43% of patients responded to treatment with the bispecific antibody, though a large portion of patients experienced a grade 3/4 adverse event.
Acalabrutinib Treatment Superior to Obinutuzumab Plus Chlorambucil in Treatment-Naïve CLL
Patients who received the second-generation Bruton tyrosine kinase inhibitor, either alone or in combination with obinutuzumab, had an 80% to 90% improvement in progression-free survival.
Patients who received the second-generation Bruton tyrosine kinase inhibitor, either alone or in combination with obinutuzumab, had an 80% to 90% improvement in progression-free survival.
Are Clinical Trials Exclusion Criteria for Patients With AML Too Strict?
Many comorbidities and abnormalities included in trial eligibility criteria for AML therapies do not affect treatment response or survival, creating unnecessary barriers to trial recruitment.
Many comorbidities and abnormalities included in trial eligibility criteria for AML therapies do not affect treatment response or survival, creating unnecessary barriers to trial recruitment.
Registry Analysis Finds Off-Label Rituximab Improves Outcomes in Patients With iTTP
In subgroup analyses, the authors also noted that Caucasian patients with relapsed iTTP had significantly longer relapse-free survival, compared with African American patients.
In subgroup analyses, the authors also noted that Caucasian patients with relapsed iTTP had significantly longer relapse-free survival, compared with African American patients.
No comments:
Post a Comment